ESTRO35 Programme Book

11:25 > A radiation dose-response relationship for risk of heart failure in survivors of Hodgkin lymphoma B.M.P. Aleman (The Netherlands), F.A. Van Nimwegen, G. Ntentas, S.C. Darby, M. Schaapveld, M. Hauptmann, P.J. Lugtenburg, C.P.M. Janus, A.D.G. Krol, F.E. Van Leeuwen, D.J. Cutter 11:35 > Cardiac risk prediction: Moving beyond a mean heart dose model? M. Maraldo (Denmark), F. Giusti, I. Vogelius, M. Lundemann, S. Bentzen, M. Van der Kaaij, B. Aleman, M. Henry-Amar, P. Meijnders, E. Moser, C. Fortpied, L. Specht

OC-0059

SATURDAY 30 APRIL 2016

OC-0060

Proffered Papers BRACHYTHERAPY 1: PROSTATE 10:45 - 11:45 | ROOM 4 Chair: F.A. Siebert (Germany) Chair: R. Alonzi (UK)

10:45 > Focal Brachytherapy: what dose to what volume?

A. Haworth (Australia), H. Reynolds, M. DiFranco, Y. Sun, D. Wraith, S. Williams, B. Parameswaran, C. Mitchell, M. Ebert

OC-0061

10:55 > High-dose-rate HDR boost for localized prostate cancer decreases long term rectum toxicity S. Aluwini (The Netherlands), M. Hoogeman, J. Lebesque, C. Bangma, L. Incrocci, W. Heemsbergen

OC-0062

11:05 > Real-time in-vivo dosimetry in HDR prostate brachytherapy J. Mason, B. Al-Qaisieh, A. Henry, P. Bownes (UK)

OC-0063

11:15 > A prediction model for biochemical failure after salvage Iodine-125 prostate brachytherapy M. Peters (The Netherlands), J.R.N. Van der Voort van Zyp, M.A. Moerland, C.J. Hoekstra, S. Van de Pol, H. Westendorp, M. Maenhout, R. Kattevilder, H.M. Verkooijen, P.S.N. Van Rossum, H.U. Ahmed, T. Shah, M. Emberton, M. Van Vulpen 11:25 > Risk of second malignancies after seed prostate brachytherapy as monotherapy in a single institution A. Fernandez Ots (Australia), J. Bucci, D. Malouf, L. Browne, Y. Chin

OC-0064

OC-0065

INTERDISCIPLINARY RADIOBIOLOGY

CLINICAL BRACHYTHERAPY PHYSICS

RTT

YOUNG

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

68

Made with